Receipt notice ok
7 documentos
| Group | Order | Exhibit title | Document | Files | Editor |
|---|---|---|---|---|---|
| 0 | 0 | Forms and Cover | Form G-1450, Authorization for Credit Card Transaction of $715.00 towards I-140 filing fee. Form G-1450, Authorization for Credit Card Transactions - USCIS | 1c / 0t | Editar |
| 0 | 1 | Forms and Cover | Form G-1450, Authorization for Credit Card Transaction of $300 towards Asylum Program fee. Form G-1450, Authorization for Credit Card Transactions - USCIS | 1c / 0t | Editar |
| 0 | 2 | Forms and Cover | Petition Cover Sheet Petition Cover Sheet | 1c / 0t | Editar |
| 0 | 3 | Forms and Cover | G-1145, E-Notification of Application/Petition Acceptance G-1145, E-Notification of Application/Petition Acceptance | 1c / 0t | Editar |
| 0 | 4 | Forms and Cover | Form G-28: Notice of Entry of Appearance as Attorney or Accredited Representative Form G-28: Notice of Entry of Appearance as Attorney or Accredited Representative | 1c / 0t | Editar |
| 0 | 5 | Forms and Cover | Form I-140: Immigrant Petition for Alien Worker Form I-140: Immigrant Petition for Alien Worker | 1c / 0t | Editar |
| 0 | 6 | Forms and Cover | Cover Letter Cover Letter | 1c / 0t | Editar |
93 documentos
| Group | Order | Exhibit title | Document | Files | Editor |
|---|---|---|---|---|---|
| 1 | 1 | Exhibit A. Evidence on Dr. Noma translation only | A.1. Beneficiary’s Personal Statement Self-Statement | 1c / 1t | Editar |
| 1 | 2 | Exhibit A. Evidence on Dr. Noma translation only | A.2. Dr. Noma’s Curriculum Vitae Curriculum Vitae | 1c / 1t | Editar |
| 1 | 3 | Exhibit A. Evidence on Dr. Noma translation only | A.3. Bachelor’s Degree in Biomedical Sciences Diploma and transcripts | 1c / 1t | Editar |
| 1 | 4 | Exhibit A. Evidence on Dr. Noma translation only | A.4. Postgraduate Certificate in Biomedical Engineering Diploma and transcripts | 1c / 1t | Editar |
| 1 | 5 | Exhibit A. Evidence on Dr. Noma translation only | A.5. Master’s Degree in Health Sciences Diploma and transcripts | 1c / 1t | Editar |
| 1 | 6 | Exhibit A. Evidence on Dr. Noma translation only | A.6. Doctorate in Sciences Diploma and transcripts | 1c / 1t | Editar |
| 1 | 7 | Exhibit A. Evidence on Dr. Noma translation only | A.7. Postdoctoral Fellowship Diploma and transcripts | 1c / 1t | Editar |
| 1 | 8 | Exhibit A. Evidence on Dr. Noma translation only | A.8. MBA in Data Science and Analytics Diploma and transcripts | 1c / 1t | Editar |
| 2 | 1 | Exhibit B. Evidence that the beneficiary was the recipient of the awards | B.1. Award certificate/confirmation of Poster Award / Honorable Mention for: “Targeting Peroxiredoxin 2 as a potential treatment for NRAS mutated metastatic melanoma,” Symposium commemorating the 50th Anniversary of the Postgraduate Program in Pharmacy – Pathophysiology and Toxicology, Faculty of Pharmaceutical Sciences, University of São Paulo (FCF/USP), São Paulo, Brazil (November 2022). Evidence of receipt of lesser nationally or internationally recognized prizes or awards for excellence | 1c / 0t | Editar |
| 2 | 2 | Exhibit B. Evidence that the beneficiary was the recipient of the awards | B.2. Photograph(s) of Dr. Noma presenting her poster at the Symposium Evidence of receipt of lesser nationally or internationally recognized prizes or awards for excellence | 1c / 0t | Editar |
| 2 | 3 | Exhibit B. Evidence that the beneficiary was the recipient of the awards translation only | B.3. Official Symposium Activity Report (November 2022) for the Symposium commemorating the 50th Anniversary of the Postgraduate Program in Pharmacy – Pathophysiology and Toxicology (FCF/USP), documenting the Symposium structure, the poster sessions and faculty evaluation process, and the official listing of awardees including Dr. Noma’s Honorable Mention Evidence of receipt of lesser nationally or internationally recognized prizes or awards for excellence | 1c / 1t | Editar |
| 2 | 4 | Exhibit B. Evidence that the beneficiary was the recipient of the awards | B.4. Award letter/notice from CNPq granting Dr. Noma the Postdoctoral Fellowship Abroad, including award period and benefits Evidence of receipt of lesser nationally or internationally recognized prizes or awards for excellence | 1c / 0t | Editar |
| 2 | 5 | Exhibit B. Evidence that the beneficiary was the recipient of the awards | B.5. Background information on CNPq establishing CNPq as a Brazilian federal government science and research funding agency Evidence of receipt of lesser nationally or internationally recognized prizes or awards for excellence | 1c / 0t | Editar |
| 2 | 6 | Exhibit B. Evidence that the beneficiary was the recipient of the awards | B.6. CNPq Selection and Judging Requirements for scholarships/fellowships abroad, showing the formal, multi-stage, comparative merit-review and ranking process Evidence of receipt of lesser nationally or internationally recognized prizes or awards for excellence | 1c / 0t | Editar |
| 3 | 1 | Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research | C.1. BJPS ScholarOne notice confirming account creation and addition to the reviewer database (April 5, 2024). Evidence that you have been asked to judge the work of others, either individually or on a panel | 1c / 0t | Editar |
| 3 | 2 | Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research | C.2. Formal invitation from the Associate Editor of the Brazilian Journal of Pharmaceutical Sciences to review Manuscript ID BJPS-2024-0245 (April 5, 2024) Evidence that you have been asked to judge the work of others, either individually or on a panel | 1c / 0t | Editar |
| 3 | 3 | Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research | C.3. Editorial reminder from the Brazilian Journal of Pharmaceutical Sciences confirming Dr. Noma’s active peer review assignment (April 19, 2024) Evidence that you have been asked to judge the work of others, either individually or on a panel | 1c / 0t | Editar |
| 3 | 4 | Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research | C.4. Completed Peer Review Report for Manuscript ID BJPS-2024-0245, including technical ratings, editorial recommendation, and substantive comments to the author (April 21, 2024) Evidence that you have been asked to judge the work of others, either individually or on a panel | 1c / 0t | Editar |
| 3 | 5 | Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research | C.5. Official Certificates of Service as Ad Hoc Abstract Reviewer for the VI and VII International Meetings of Biosciences and Physiopathology (2019–2020) Evidence that you have been asked to judge the work of others, either individually or on a panel | 1c / 0t | Editar |
| 3 | 6 | Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research | C.6. Reviewer orientation and instruction communications from the Organizing Committee of the VI International Meeting of Biosciences and Physiopathology (September 2019) Evidence that you have been asked to judge the work of others, either individually or on a panel | 1c / 0t | Editar |
| 3 | 7 | Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research | C.7. Email acknowledgment from the Organizing Committee confirming the final round of abstract corrections for the VII International Meeting of Biosciences and Physiopathology (August 2020) Evidence that you have been asked to judge the work of others, either individually or on a panel | 1c / 0t | Editar |
| 3 | 8 | Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research | C.8. Institutional Statement from the Coordinator of the Postgraduate Program in Biosciences and Physiopathology (PBF) confirming Dr. Noma’s evaluative responsibilities and contributions to scientific quality control (December 15, 2025) Evidence that you have been asked to judge the work of others, either individually or on a panel | 1c / 0t | Editar |
| 4 | 1 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.1. "Peroxiredoxin-2 represses NRAS-mutated melanoma cells invasion by modulating EMT markers," IHY Noma et al., Biomedicine & Pharmacotherapy (2024) Evidence of your original scientific, scholarly, artistic, athletic, or business-related contributions of major significance to the field | 1c / 0t | Editar |
| 4 | 2 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.2. Recommendation letter from Dr. Jérémie Nsengimana, PhD (Newcastle University, UK), confirming the "transformative" nature and independent validation of the PRDX2 discovery Letter of Support (EBs, O, P, E) | 2c / 0t | Editar |
| 4 | 3 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.3. "Modeling melanoma heterogeneity in vitro: redox, resistance and pigmentation profiles," LAC Carvalho, IHY Noma et al., Antioxidants (2024). Evidence of your original scientific, scholarly, artistic, athletic, or business-related contributions of major significance to the field | 1c / 0t | Editar |
| 4 | 4 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.4. "2-Methoxyestradiol-3,17-O,O-bis-sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFI-Resistant Melanoma," YA Franco et al. (including IHY Noma), IJMS (2023). Evidence of your original scientific, scholarly, artistic, athletic, or business-related contributions of major significance to the field | 1c / 0t | Editar |
| 4 | 5 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.5. Recommendation letter from Prof. Silvia Berlanga de Moraes Barros, PhD (University of São Paulo), explaining the significance of the heterogeneity and resistance research Letter of Support (EBs, O, P, E) | 2c / 0t | Editar |
| 4 | 6 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.6. Recommendation letter from Dr. Patrícia Abrão Possik, PhD (Brazilian National Cancer Institute/INCA), highlighting the translational impact of the redox and resistance findings Letter of Support (EBs, O, P, E) | 2c / 0t | Editar |
| 4 | 7 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.7. University of São Paulo (USP) Postdoctoral Program Completion Certificate (translated), explicitly titled project: “The Role of HDAC8 in UVR-Driven Melanoma Initiation,” documenting completion and scope of the HDAC8/UVR research Evidence of your original scientific, scholarly, artistic, athletic, or business-related contributions of major significance to the field | 1c / 0t | Editar |
| 4 | 8 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.8. Recommendation letter from Prof. Silvya Stuchi Maria-Engler, PhD (University of São Paulo), corroborating the impact of the HDAC8/UV-induced melanoma discovery Letter of Support (EBs, O, P, E) | 2c / 0t | Editar |
| 4 | 9 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.9. “Association of high risk Human Papillomavirus and Ureaplasma parvum co infections with increased risk of low grade squamous intraepithelial cervical lesions,” Asian Pacific Journal of Cancer Prevention (2021). Evidence of your original scientific, scholarly, artistic, athletic, or business-related contributions of major significance to the field | 1c / 0t | Editar |
| 4 | 10 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.10. Recommendation letter from Prof. Marcia Edilaine Lopes Consolaro, PhD (State University of Maringá/UEM), documenting Dr. Noma’s original Master’s research and the first-published evidence linking high-risk HPV and Ureaplasma parvum co-infections to cervical lesion risk Letter of Support (EBs, O, P, E) | 2c / 0t | Editar |
| 4 | 11 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.11. “14 Week exercise training modifies the DNA methylation levels at gene sites in non Alzheimer’s disease women aged 50 to 70 years,” Experimental Gerontology (2024). Evidence of your original scientific, scholarly, artistic, athletic, or business-related contributions of major significance to the field | 1c / 0t | Editar |
| 4 | 12 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.12. “14 weeks combined exercise epigenetically modulated 118 genes of menopausal women with prediabetes,” Frontiers in Endocrinology (2022). Evidence of your original scientific, scholarly, artistic, athletic, or business-related contributions of major significance to the field | 1c / 0t | Editar |
| 4 | 13 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.13. Recommendation letter from Ana Campa, PhD (Full Professor, Faculty of Pharmaceutical Sciences, University of São Paulo), corroborating the originality and technical significance of the PRDX2/EMT discovery, the HPV/Ureaplasma co-infection findings, and the impact of the exercise-induced epigenetic research Letter of Support (EBs, O, P, E) | 1c / 0t | Editar |
| 4 | 14 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.14. Google Scholar citation report for Dr. Noma as of February 26, 2026, documenting 127 total citations, an h-index of 7, and an i10-index of 6 Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 4 | 15 | Exhibit D. Evidence of the original scientific contributions of major significance in the field | D.15. Google Scholar citation report for Dr. Noma as of October 2025, documenting 97 total citations, an h-index of 6, and an i10-index of 5 Evidence of your original scientific, scholarly, artistic, athletic, or business-related contributions of major significance to the field | 1c / 0t | Editar |
| 5 | 1 | E. Evidence that the beneficiary is an author of scholarly articles in the field of science published in professional media | E.1. Dr. Noma’s Curriculum Vitae (Lattes). Contains the complete list of all scholarly articles authored by Dr. Noma, including journal titles, years, co authors, and citation counts in Web of Science and Scopus Curriculum Vitae | 1c / 0t | Editar |
| 5 | 2 | E. Evidence that the beneficiary is an author of scholarly articles in the field of science published in professional media | E.2. Web of Science (Clarivate) Researcher Profile. Independent report from Clarivate Analytics verifying 20 publications indexed in the prestigious Web of Science Core Collection, 146 total citations, and an h-index of 6 Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 5 | 3 | E. Evidence that the beneficiary is an author of scholarly articles in the field of science published in professional media | E.3. SCImago "How We Work" Methodology Report. Documentation explaining the scientific validity of SCImago indicators, its partnership with the Scopus (Elsevier) database, and the peer-reviewed research supporting its ranking system. This establishes the reliability of the journal metrics used throughout this petition Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 6 | 1 | E.4. Evidence of publication in Biomedicine & Pharmacotherapy (2024) | E.4.1. “Peroxiredoxin 2 represses NRAS mutated melanoma cell invasion by modulating EMT markers,” Biomedicine & Pharmacotherapy (2024) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 6 | 2 | E.4. Evidence of publication in Biomedicine & Pharmacotherapy (2024) | E.4.2. SCImago journal profile for Biomedicine & Pharmacotherapy showing SJR 2024: 1.775, Q1 ranking, H index 169, coverage in Medicine and Pharmacology, and indexing in Scopus/Web of Science Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 7 | 1 | E.5. Evidence of publication in Antioxidants (2024) | E.5.1. “Modeling melanoma heterogeneity in vitro: redox, resistance, and pigmentation profiles,” Antioxidants (2024) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 7 | 2 | E.5. Evidence of publication in Antioxidants (2024) | E.5.2. SCImago journal profile for Antioxidants showing SJR 2024: 1.484, Q1 status, H index 133, MDPI publisher information, and subject categories in Biochemistry, Genetics and Molecular Biology Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 8 | 1 | E.6. Evidence of publication in Frontiers in Endocrinology (2022) | E.6.1. “14 weeks combined exercise epigenetically modulated 118 genes of menopausal women with prediabetes,” Frontiers in Endocrinology (2022) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 8 | 2 | E.6. Evidence of publication in Frontiers in Endocrinology (2022) | E.6.2. SCImago profile for Frontiers in Endocrinology (SJR 2024: 1.472; Q1; H index 138; scope describing rigorous peer review and a global clinical/endocrine audience) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 9 | 1 | E.7. Evidence of publication in Environmental Epigenetics (2025) | E.7.1. “DNA methylation signatures of arsenic exposure and obesity,” Environmental Epigenetics (2025). Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 9 | 2 | E.7. Evidence of publication in Environmental Epigenetics (2025) | E.7.2. Evidence of indexing and professional status (publisher or database pages confirming peer review and inclusion in major scientific databases such as Web of Science/Scopus) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 10 | 1 | E.8. Evidence of publication in Experimental Gerontology (2024) | E.8.1. “14 Week exercise training modifies the DNA methylation levels at gene sites in non Alzheimer’s disease women aged 50 to 70 years,” Experimental Gerontology (2024) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 10 | 2 | E.8. Evidence of publication in Experimental Gerontology (2024) | E.8.2. SCImago (or equivalent) profile confirming Experimental Gerontology’s Q1 ranking in Aging/Gerontology and indexing in Web of Science and Scopus Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 11 | 1 | E.9. Evidence of publication in Research Quarterly for Exercise and Sport (2023) | E.9.1. “Eight weeks of physical training decreases 2 years of DNA methylation age of sedentary women,” Research Quarterly for Exercise and Sport (2023) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 11 | 2 | E.9. Evidence of publication in Research Quarterly for Exercise and Sport (2023) | E.9.2. SCImago profile for Research Quarterly for Exercise and Sport showing Q1 status (SJR ≈ 0.78), long standing coverage in sports sciences, and Scopus indexing Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 12 | 1 | E.10. Evidence of publication in Journal of Trace Elements in Medicine and Biology (2023/2024): | E.10.1. “The influence of serum selenium in differential epigenetic and transcriptional regulation of the CPT1B gene in women with obesity.” Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 12 | 2 | E.10. Evidence of publication in Journal of Trace Elements in Medicine and Biology (2023/2024): | E.10.2. SCImago or publisher documentation showing the journal’s subject areas (Medicine, Biochemistry), Q1/Q2 ranking, and indexing in Web of Science and Scopus Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 13 | 1 | E.11. Evidence of publication in Clinical Nutrition ESPEN (2021): | E.11.1. “Gene signatures of autopsy lungs from obese patients with COVID 19,” Clinical Nutrition ESPEN (2021). Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 13 | 2 | E.11. Evidence of publication in Clinical Nutrition ESPEN (2021): | E.11.2. SCImago profile for Clinical Nutrition ESPEN (SJR 2024: 0.805; Q2 in Nutrition and Dietetics and Endocrinology/Metabolism; H index 46; official ESPEN journal; indexed in Scopus/Web of Science). Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 14 | 1 | E.12. Evidence of publication in Journal of Visualized Experiments (JoVE) (2022) | E.12.1. “Sample preparation to bioinformatics analysis of DNA methylation: association strategy for obesity and related trait studies,” Journal of Visualized Experiments (2022) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 14 | 2 | E.12. Evidence of publication in Journal of Visualized Experiments (JoVE) (2022) | E.12.2. SCImago profile for Journal of Visualized Experiments (SJR 2024: 0.431; Q2; H index 141; scope in novel and gold standard research methodologies, indexed in Scopus/Web of Science). Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 15 | 1 | E.13. Evidence of publication in Asian Pacific Journal of Cancer Prevention (APJCP) (2021): | E.13.1. “Association of high risk Human Papillomavirus and Ureaplasma parvum co infections with increased risk of low grade squamous intraepithelial cervical lesions,” Asian Pacific Journal of Cancer Prevention (2021) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 15 | 2 | E.13. Evidence of publication in Asian Pacific Journal of Cancer Prevention (APJCP) (2021): | E.13.2. SCImago profile for Asian Pacific Journal of Cancer Prevention (SJR 2024: 0.530; H index 98; Q2 in Cancer Research, Q3 in Public Health/Epidemiology; continuous coverage since 2000). Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 16 | 1 | E.14. Evidence of publication in International Journal of Molecular Sciences (2023): | E.14.1. “2 Methoxyestradiol 3,17 O,O bis sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFI Resistant Melanoma Cells,” International Journal of Molecular Sciences (2023) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 16 | 2 | E.14. Evidence of publication in International Journal of Molecular Sciences (2023): | E.14.2. SCImago profile for International Journal of Molecular Sciences (SJR 2024: 1.273; Q1; H index 314; broad molecular biology and molecular medicine scope; MDPI; Scopus/Web of Science indexing) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 17 | 1 | E.15. Evidence of publication in Frontiers in Nutrition (2024): | E.15.1. “Association between the relative abundance of phyla actinobacteria, vitamin C consumption, and DNA methylation of genes linked to immune response pathways,” Frontiers in Nutrition (2024). Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 17 | 2 | E.15. Evidence of publication in Frontiers in Nutrition (2024): | E.15.2. SCImago profile for Frontiers in Nutrition (SJR 2024: 1.12; H-index 84; Q1 in Nutrition and Dietetics; published by Frontiers Media, Switzerland; Scopus-indexed) Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 18 | 0 | E. 16. Evidence that the beneficiary is an author of scholarly articles in the field of science published in professional media | E.16. Expert letter from Prof. Marcia Edilaine Lopes Consolaro, PhD attesting to the originality, quality, and influence of Dr. Noma’s scholarly publications and explaining how her articles have guided subsequent research in melanoma, epigenetics, and related fields Evidence of your authorship of scholarly articles in professional or major trade publications or other major media | 1c / 0t | Editar |
| 19 | 1 | F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions | F.1. Certificate of Poster Presentation, 19th International Congress of the Society for Melanoma Research (SMR), Edinburgh, Scotland (2022). Evidence that your work has been displayed at artistic exhibitions or showcases | 1c / 0t | Editar |
| 19 | 2 | F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions | F.2. Official Abstract Book, 19th International Congress of the SMR, featuring Dr. Noma’s research (p. 1) (2022) Evidence that your work has been displayed at artistic exhibitions or showcases | 1c / 0t | Editar |
| 19 | 3 | F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions | F.3. Society for Melanoma Research (SMR) "About" and "Congress" Documentation, confirming the Scientific Review Committee and competitive selection process Evidence that your work has been displayed at artistic exhibitions or showcases | 2c / 0t | Editar |
| 19 | 4 | F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions | F.4. Certificate of Presentation and Honorable Mention, FCF/USP 50th Anniversary Symposium (2022) Evidence that your work has been displayed at artistic exhibitions or showcases | 2c / 0t | Editar |
| 19 | 5 | F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions | F.5. Certificate of Presentation, XXII Brazilian Congress of Toxicology (CBTox), organized by the Brazilian Society of Toxicology (SBTox) (2022). Evidence that your work has been displayed at artistic exhibitions or showcases | 1c / 0t | Editar |
| 19 | 6 | F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions | F.6. Brazilian Society of Toxicology (SBTox) "About" Documentation, confirming its affiliation with the International Union of Toxicology (IUTOX). Evidence that your work has been displayed at artistic exhibitions or showcases | 1c / 0t | Editar |
| 19 | 7 | F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions | F.7. Official Proceedings (Anais), III International Symposium of Experimental Pathology (ISEP), featuring Dr. Noma’s research (p. 40) (2019). Evidence that your work has been displayed at artistic exhibitions or showcases | 1c / 0t | Editar |
| 19 | 8 | F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions | F.8. Certificate of Presentation, XXVII Brazilian Congress in Biomedical Engineering (CBEB) (2020). Evidence that your work has been displayed at artistic exhibitions or showcases | 1c / 0t | Editar |
| 19 | 9 | F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions | F.9. Certificate of Presentation, VI International Meeting of Biosciences and Physiopathology - X Symposium of Biosciences Applied to Pharmacy (2019). Evidence of your performance of a leading or critical role in distinguished organizations | 1c / 0t | Editar |
| 19 | 10 | F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions | F.10. Certificate of Presentation, FCF/USP 50th Anniversary Symposium (2022) Evidence that your work has been displayed at artistic exhibitions or showcases | 1c / 0t | Editar |
| 20 | 1 | Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation | G.1. Postdoctoral Fellow Offer Letter, H. Lee Moffitt Cancer Center and Research Institute (April 28, 2025) Evidence of your membership in associations in the field which demand outstanding achievement of their members | 1c / 0t | Editar |
| 20 | 2 | Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation | G.2. Letter Confirming International Scientific Award Recognition and Critical Role – Dr. Keiran Smalley, Director, Melanoma and Skin Cancer Center of Excellence, Moffitt Cancer Center (November 6, 2025) Letter of Support (EBs, O, P, E) | 2c / 0t | Editar |
| 20 | 3 | Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation | G.3. Institutional Profile and Economic Impact Documentation, "About Moffitt," confirming NCI Comprehensive Cancer Center designation and $2.4 billion economic impact Evidence of your performance of a leading or critical role in distinguished organizations | 1c / 0t | Editar |
| 20 | 4 | Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation | G.4. National Ranking Reports, Newsweek "America's Best Cancer Hospitals" (2023 and 2024), identifying Moffitt as #1 in Florida and the Southeast and Top 10 in the Nation Evidence of your performance of a leading or critical role in distinguished organizations | 2c / 0t | Editar |
| 20 | 5 | Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation | G.5. Institutional Awards and Recognition Records, confirming Moffitt as a Forbes "America's Best Large Employer" and Becker’s "150 Top Places to Work in Healthcare" Evidence of your performance of a leading or critical role in distinguished organizations | 1c / 0t | Editar |
| 20 | 6 | Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation | G.6. Departmental Overview, "Tumor Microenvironment and Metastasis Department," detailing the specialized research program and elite clinician-scientist faculty Evidence of your performance of a leading or critical role in distinguished organizations | 1c / 0t | Editar |
| 20 | 7 | Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation | G.7. Strategic Partnership Announcements, documenting high-profile oncology collaborations between Moffitt Cancer Center, AstraZeneca, and CMIC Group Evidence of your performance of a leading or critical role in distinguished organizations | 2c / 0t | Editar |
| 20 | 8 | Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation | G.8. Institutional Fellowship Standards, "Postdoctoral Training" and "Become a Moffitt Postdoc," identifying fellows as "outstanding scientific leaders" within the NCI-designated research environment. Evidence of your performance of a leading or critical role in distinguished organizations | 2c / 0t | Editar |
| 21 | 0 | Exhibit H. Final Merits Determination | Previously Approved Dr. Noma’s O-1A Nonimmigrant Petition Approval notice: I-797, Notice of Action | 1c / 0t | Editar |
| 22 | 0 | Exhibit I. Personal Documents translation only | Birth Certificate and Corresponding Translation Birth certificate | 1c / 1t | Editar |
| 22 | 1 | Exhibit I. Personal Documents | Passport’s Biometrics Page Passport | 1c / 0t | Editar |
| 22 | 2 | Exhibit I. Personal Documents | U.S. Visa Page Evidence of legal status | 2c / 0t | Editar |
| 22 | 3 | Exhibit I. Personal Documents | I-94 Copy of I-94 | 2c / 0t | Editar |
| 22 | 4 | Exhibit I. Personal Documents translation only | Marriage certificate and Corresponding Translation Marriage certificate | 1c / 1t | Editar |
| 22 | 5 | Exhibit I. Personal Documents translation only | Derivative’s Birth Certificate Birth certificate | 1c / 1t | Editar |
| 22 | 6 | Exhibit I. Personal Documents | Derivative’ s Passport’s Biometrics Page Passport | 1c / 0t | Editar |
| 22 | 7 | Exhibit I. Personal Documents | Derivative’ s U.S. Visa Page Evidence of legal status | 1c / 0t | Editar |
| 22 | 8 | Exhibit I. Personal Documents | Derivative’ s I-94 Copy of I-94 | 2c / 0t | Editar |
Estes documentos não entrarão no PDF até que sejam corrigidos.
| Documento | Status | Razão |
|---|---|---|
F.6. Brazilian Society of Toxicology (SBTox) "About" Documentation, confirming its affiliation with the International Union of Toxicology (IUTOX). — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid") |
reclyIaezYUe5hKGF — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files |
DNA methylation signatures of arsenic exposure and obesity — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title) |
Evidence of participation - Ad hoc reviewer of simple abstract at the VII International Meeting of Biosciences and Physiopathology and XI Symposium of Biosciences Applied to Pharmacy — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title) |
Evidence of receipt of lesser nationally or internationally recognized prizes or awards for excellence — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title) |
Evidence that you have commanded a salary or other remuneration for services that demonstrates your exceptional ability — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files |
Form I-131: Application for Travel Document — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files |
Form I-485: Application to Register Permanent Residence or Adjust Status — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files |
Form I-693: Report of Medical Examination and Vaccination Record — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files |
Form I-765: Application for Employment Authorization — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files |
Peroxiredoxin-2 represses NRAS-mutated melanoma cells invasion by modulating EMT markers — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title) |
Recognition for your achievements and significant contributions to your industry or field by your peers, government entities, professional or business organizations — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files |
Reviewer - Manuscript ""Dry powder inhalation formulation co-loaded with erlotinib and curcumin for treatment of non-small cell lung cancer." — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title) |
VER ONDE POR, SE TEM LOCAL NA COVER OU NOS PESSOAIS Approval notice: I-797, Notice of Action — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title) |
VERIFICAR O Q FZR > TLVZ CRIAR UM OTHER ELIGLE EVIDENCES Legal research about the national importance of immigrant profession 1 (Record only) — | Unnecessary to the case | Status: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title) |